CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 04/01/19

Nano cap Cyclacel Pharmaceuticals ( CYCC -3.9% ) slips on average volume in response to results from a Phase 1 clinical trial evaluating a sequential regimen of sapacitabine and seliciclib in patients with BRCA-positive metastatic breast cancer. The data, apparently underwhelming to in...

BERKELEY HEIGHTS, N.J., April 01, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced Phase 1 clinical data from the company's DNA ...

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2018 Earnings Conference Call March 27, 2019, 16:30 ET Company Participants Alexander Fudukidis - IR Spiro Rombotis - President, CEO & Executive Director Paul McBarron - EVP, Finance, CFO, COO, Secretary & Executive Director Judy...

– Conference Call Scheduled March 27, 2019 at 4:30 p.m. EDT – BERKELEY HEIGHTS, N.J., March 27, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines...

Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company using its expertise in cell cycle, transcriptional regulation and DNA damage response biology in cancer cells to develop medicines, according to the company’s website (see here: www.cycla...

-- PALOMA-3 study gene expression profiling shows that CDK2 is a key kinase bypass mechanism after treatment with palbociclib plus hormone therapy -- -- Cyclin E is proposed as the first predictive biomarker of palbociclib efficacy -- BERKELEY HEIGHTS, N.J., March 25, 2019 ...

BERKELEY HEIGHTS, N.J., March 20, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2018 fin...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Interest rates are back in the spotlight with a Federal Reserve interest rate decis...

BERKELEY HEIGHTS, N.J., March 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it will participate in the 31 st Annual...